Saber, Saber H.
Yak, Nyakuoy https://orcid.org/0000-0001-9412-4300
Dolski, Konstantin
Mäki, Sanna https://orcid.org/0009-0006-9455-8778
Levanov, Lev
Willenbrink, Levina A.
Sng, Julian D. J. https://orcid.org/0000-0001-7837-4473
Shaker, Mohammed R. https://orcid.org/0000-0002-3675-4598
Morrison, Sean D. https://orcid.org/0000-0001-9128-8713
Zheng, Huiwen
Pars, Selin https://orcid.org/0009-0003-9618-7956
Pietrogrande, Giovanni https://orcid.org/0000-0001-5107-2002
Bong, Yih Tyng https://orcid.org/0009-0002-0952-1593
Vane-Tempest, Tania
Smura, Teemu https://orcid.org/0000-0002-9187-3151
Strandin, Tomas
Ojha, Ravi
Kant, Ravi https://orcid.org/0000-0003-3878-9775
Ruuska, Janika https://orcid.org/0000-0002-3978-2033
Topi, Francesco
Vaskiv, Diana
Kareinen, Lauri https://orcid.org/0000-0003-2525-7817
Binder, Tobias
Lu, Siyuan
Floetenmeyer, Matthias
Al-mhanawi, Bahaa
Zhu, Yanshan
Sironen, Tarja https://orcid.org/0000-0002-2344-2755
Talbo, Gert Hoy
Short, Kirsty R. https://orcid.org/0000-0003-4963-6184
Kallemeijn, Wouter W.
Solari, Roberto
Mar, Jessica
Tate, Edward W. https://orcid.org/0000-0003-2213-5814
van Waardenberg, Ashley J. https://orcid.org/0000-0002-9382-7490
Vapalahti, Olli https://orcid.org/0000-0003-2270-6824
Wolvetang, Ernst https://orcid.org/0000-0002-2146-6614
Balistreri, Giuseppe https://orcid.org/0000-0002-3585-559X
Joensuu, Merja https://orcid.org/0000-0002-4533-0455
Article History
Received: 16 July 2024
Accepted: 28 April 2026
First Online: 11 May 2026
Competing interests
: E.W.T. is a founding director and shareholder of Myricx Pharma Ltd and a named inventor on patents covering NMT inhibitors (WO2017001812A1, PCT/GB2019/053613), is an advisor of and holds share options in Sasmara Therapeutics and receives current or recent funding from Myricx Pharma Ltd, Pfizer Ltd, Kura Oncology, AstraZeneca, Merck & Co. and GSK. W.W.K. and E.W.T. are named inventors on an Imperial College patent covering NMT inhibitors in the treatment of cancer, autoimmune- and inflammatory disorders (WO 2022/090746A1). Other authors declare no competing interests.